The global enteric empty capsules market size is likely to be valued at US$3.5 billion in 2026, and is expected to reach US$5.6 billion by 2033, growing at a CAGR of 6.9% during the forecast period from 2026 to 2033, driven by rising global demand for advanced drug delivery systems, expanding nutraceutical manufacturing, and the growing adoption of plant-based and acid-resistant capsule technologies across pharmaceutical and nutraceutical applications.

Enteric empty capsules are specialized pharmaceutical-grade capsules engineered with acid-resistant polymer coatings or compositions that protect their contents from dissolution in the acidic gastric environment of the stomach, ensuring targeted drug release in the alkaline environment of the small intestine or colon.

Driver - Expanding Global Generic Pharmaceutical Production

Generic pharmaceutical manufacturers producing acid-sensitive APIs, including proton pump inhibitors (PPIs), certain antibiotics, enzyme replacement therapies, and gastrointestinal drugs, rely on enteric capsules to provide acid resistance and targeted intestinal drug release while maintaining cost efficiency for high-volume production.

The global generic pharmaceutical market continues to expand due to patent expirations, government cost-containment initiatives, and improved healthcare access in emerging economies. India, which supplies nearly 20% of the world's generic medicines by volume and exports to over 200 countries, represents a major market for enteric capsules. Domestic manufacturers such as Nectar Lifesciences Ltd. and Natural Capsules Limited support the country's large generic drug manufacturing industry.

Restraint - Stringent Regulatory and Quality Compliance Requirements Across Global Markets

The market faces regulatory challenges due to strict and region-specific quality requirements set by agencies such as the U.S. FDA, the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and other national regulators. Pharmaceutical-grade enteric capsules must meet pharmacopoeial standards for dissolution, disintegration, heavy metal content, residual solvents, microbial limits, and stability. Compliance requires extensive testing, documentation, and quality assurance from capsule manufacturers.

In addition, evolving harmonization efforts under the International Council for Harmonisation (ICH) Q guidelines increase compliance requirements for manufacturers serving multiple global markets. Maintaining these standards requires continuous investment in quality systems, creating high entry barriers for smaller manufacturers and increasing operating costs for established players.

Opportunity - HPMC and Pullulan-based Enteric Capsule Innovation for Specialized Drug Delivery

The development of next-generation HPMC and pullulan-based enteric capsules presents a strong opportunity for product innovation and market differentiation. These capsules offer improved pH-specific drug release, better moisture barrier properties, and enhanced compatibility with hygroscopic and moisture-sensitive APIs. Products such as Lonza's Vcaps Enteric HPMC and Roquette Frères' Gastrores HPMC capsules provide acid resistance while meeting vegetarian, vegan, halal, kosher, and non-GMO requirements.

Manufacturers can further differentiate their offerings by developing enteric capsules with tailored release profiles. These include delayed-release capsules for targeted intestinal delivery, sustained-release systems for treating inflammatory bowel disease (IBD) and colorectal cancer, and pulsatile-release capsules for chronotherapeutic drug delivery. Such advanced formulations support premium pricing and strengthen long-term partnerships with specialty pharmaceutical companies.

Product Type Insights

Hydroxypropyl Methylcellulose (HPMC) capsules are expected to dominate the market, accounting for approximately 48% of the total share in 2026. Their growth is driven by excellent acid resistance, plant-based composition, low moisture content, and compatibility with moisture-sensitive APIs. They also meet vegetarian, vegan, halal, and kosher requirements. Lonza's Capsugel® Vcaps® Enteric HPMC capsules are a notable example of this segment.

Vegetable capsules are projected to be the fastest-growing product type, supported by rising demand for plant-based products across the pharmaceutical and nutraceutical industries. Growth is driven by increasing consumer preference for non-animal-derived capsule formats beyond traditional HPMC capsules. Lonza's Capsugel® Plantcaps® Pullulan Capsules illustrate this trend by offering vegan, non-GMO, halal, and kosher solutions.

Application Insights

Antibiotic and antibacterial drug formulations are expected to dominate the application segment, accounting for approximately 38% of the market share in 2026. Enteric capsules protect acid-sensitive antibiotics, such as erythromycin and certain tetracyclines, from gastric degradation while reducing stomach irritation to improve drug delivery. Mayne Pharma's ERYC® Erythromycin Delayed-Release Capsules demonstrate the effective use of enteric capsule technology for acid-sensitive antibiotics.

Antacid and antiflatulent preparations are projected to be the fastest-growing application segment. Growth is driven by the expanding gastrointestinal health and OTC medication market, increasing self-medication for acid reflux and digestive discomfort, and rising demand for probiotics and digestive enzyme supplements. Jarrow Formulas' Jarro-Dophilus® EPS uses enteric-coated capsules to protect probiotics from stomach acid, highlighting the growing adoption of enteric capsules in digestive health products.

End-user Insights

Pharmaceutical manufacturers are expected to dominate the end-user segment, accounting for approximately 62% of the market share in 2026. Growth is driven by the widespread use of enteric capsules in the production of branded, generic, specialty, and contract pharmaceutical products. Lonza's Capsugel® Vcaps® Enteric capsules are widely used by pharmaceutical manufacturers, highlighting the importance of enteric capsules in global drug manufacturing.

Nutraceutical manufacturers are projected to be the fastest-growing end-user segment. Rising demand for probiotics, digestive enzymes, fish oil and gut health supplements is accelerating the adoption of enteric capsule formats. Lonza's Capsugel® DRcaps® capsules are widely used in digestive health and probiotic supplements, demonstrating the growing uptake of enteric capsules in the nutraceutical industry.

North America Enteric Empty Capsules Market Trends

North America is expected to dominate the market, accounting for approximately 36% of the global revenue in 2026. Growth is supported by its large pharmaceutical manufacturing base, well-established nutraceutical industry, high dietary supplement consumption, and the presence of leading enteric capsule manufacturers such as Lonza.

U.S Enteric Empty Capsules Market Insights

The U.S. is expected to lead the North America market, accounting for approximately 87% of regional revenue in 2026. Growth is driven by its large pharmaceutical manufacturing industry, high dietary supplement consumption, and well-established regulatory framework for pharmaceutical-grade capsule production.

Canada Enteric Empty Capsules Market Insights

Canada is expected to account for approximately 13% of the North American market in 2026. Growth is supported by its domestic pharmaceutical manufacturing industry, which produces generic and branded drugs under Health Canada's regulatory standards, driving demand for compliant pharmaceutical-grade capsules.

Europe Enteric Empty Capsules Market Trends

Europe is expected to be the second-largest regional market, accounting for approximately 29% of revenue in 2026. Growth is driven by its strong branded and generic pharmaceutical industry, stringent EU GMP standards, and a well-established nutraceutical sector with high dietary supplement consumption. The regional presence of manufacturers such as Farmacápsulas, Lonza, and Roquette Frères further supports the enteric capsule market.

Germany Enteric Empty Capsules Market Trends

Germany is expected to lead the European market, accounting for approximately 25% of regional revenue in 2026. Growth is driven by its strong pharmaceutical manufacturing industry, with major generic drug producers requiring enteric capsules for acid-sensitive formulations. The country's large dietary supplement market and rising demand for probiotic and gut health products further support enteric capsule demand.

U.K. Enteric Empty Capsules Market Trends

The U.K. is expected to account for over 20% of the European market in 2026. Growth is supported by its pharmaceutical manufacturing industry, which produces branded and generic medicines under MHRA GMP standards. Rising demand for probiotic supplements and digestive health products is also increasing the adoption of enteric HPMC capsules among nutraceutical manufacturers.

Asia Pacific Enteric Empty Capsules Market Trends

Asia Pacific is expected to be the fastest-growing region, driven by India's leadership in generic pharmaceutical manufacturing, China's large capsule production industry, advanced pharmaceutical and nutraceutical sectors in South Korea, and rising dietary supplement consumption across Southeast Asia.

India Enteric Empty Capsules Market Trends

India is expected to lead the Asia Pacific market, accounting for approximately 45% of regional revenue in 2026. Growth is driven by its position as a global hub for generic pharmaceutical manufacturing and exports. Companies such as Nectar Lifesciences and Natural Capsules Limited supply pharmaceutical-grade HPMC and gelatin enteric capsules that comply with WHO-GMP standards for international markets.

China Enteric Empty Capsules Market Trends

China is expected to account for approximately 20% of the Asia Pacific market in 2026. Growth is supported by its large pharmaceutical manufacturing industry and leading enteric capsule producers, including ZHEJIANG HUILI CAPSULES CO., LTD and Shaoxing Zhongya Capsule Co., Ltd., which serve both domestic and international markets. Strong demand for enteric capsules is further driven by pharmaceutical production under the National Medical Products Administration (NMPA) GMP standards.

The global enteric empty capsules market is highly competitive, with the presence of multinational specialty chemical and pharmaceutical excipient companies, dedicated capsule manufacturers, and regional suppliers serving pharmaceutical and nutraceutical industries. Lonza, headquartered in Switzerland, is a leading manufacturer of pharmaceutical-grade HPMC enteric capsules through its Vcaps Enteric product line. The company benefits from large-scale production, strong regulatory compliance across major markets, and long-standing relationships with pharmaceutical customers.

Roquette Frères competes through its Gastrores HPMC enteric capsule platform. The company leverages its expertise in pharmaceutical excipients and plant-based ingredients to meet the growing demand for clean-label and non-animal-derived capsule solutions.

Key Industry Developments:

• In May 2025, ACG introduced the personalized capsule machine (PCM), a patented technology for on-demand capsule formulation. In partnership with Art of You, ACG expanded its portfolio in personalized nutrition solutions.
• In June 2024, Lonza launched the Capsugel Enprotect capsule in a new size nine format to support pre-clinical testing of acid-sensitive APIs. It facilitated early-stage drug evaluation in rodents, accelerating development timelines and strengthening the company's position in pre-clinical solutions.